Suchergebnisse - "Van Cutsem, E"

PubPharm (31)

1

Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Yoshino, T. | Portnoy, D. | Obermannová, R. | +19

2

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

3

Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Obermannová, R. | Van Cutsem, E. | Yoshino, T. | +14

4

FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer : A retrospective subgroup analysis of the CRYSTAL study

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2016

von Köhne, C. | Poston, G. | Folprecht, G. | +4

5

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Macarulla, T. | Cervantes, A. | Tabernero, J. | +10

6

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer : the randomised phase I/II POSEIDON trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Élez, E. | Kocáková, I. | Höhler, T. | +14

7

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Peeters, M. | Price, T. | Cervantes, A. | +14

ErratumIn: Ann Oncol. 2014 Mar;25(3):757

8

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

enthalten in: British journal of cancer | 2013

von Joulain, F. | Proskorovsky, I. | Allegra, C. | +4

9

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan : data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

enthalten in: European journal of cancer (Oxford, England : 1990) | 2011

von Sargent, D. | Shi, Q. | Yothers, G. | +40

10

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer : the BEAT study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2009

von Van Cutsem, E. | Rivera, F. | Berry, S. | +10